Panmure Gordon Reiterates Buy Rating for GlaxoSmithKline (GSK)
GlaxoSmithKline (LON:GSK)‘s stock had its “buy” rating reiterated by Panmure Gordon in a research note issued on Friday, StockRatingsNetwork reports. They currently have a GBX 1,850 ($29.85) price objective on the stock. Panmure Gordon’s price objective points to a potential upside of 18.09% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at Deutsche Bank reiterated a “buy” rating on shares of GlaxoSmithKline (LON:GSK) in a research note to investors on Wednesday. They now have a GBX 1,850 ($29.85) price target on the stock. Separately, analysts at Societe Generale reiterated a “buy” rating on shares of GlaxoSmithKline (LON:GSK) in a research note to investors on Tuesday. They now have a GBX 2,000 ($32.27) price target on the stock. Finally, analysts at AlphaValue reiterated a “sell” rating on shares of GlaxoSmithKline (LON:GSK) in a research note to investors on Thursday, September 26th. They now have a GBX 1,440 ($23.23) price target on the stock. Five research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the company’s stock. GlaxoSmithKline currently has a consensus rating of “Hold” and a consensus target price of GBX 1,640.28 ($26.46).
Shares of GlaxoSmithKline (LON:GSK) traded down 0.95% during mid-day trading on Friday, hitting GBX 1556.00. The stock had a trading volume of 6,442,321 shares. GlaxoSmithKline has a 52 week low of GBX 1314.00 and a 52 week high of GBX 1816.00. The stock’s 50-day moving average is GBX 1652. and its 200-day moving average is GBX 1640.. The company’s market cap is £75.388 billion.
GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.